Correlation between enhancing lesion number and volume on standard and triple dose gadolinium-enhanced brain MRI scans from patients with multiple sclerosis

Magnetic Resonance Imaging

Volumn 17, Issue 7, 1999, Pages 985-988

  Rovaris, Marco ^a   Bastianello, Stefano ^b   Capra, Ruggero ^c   Comi, Giancarlo ^a   Yousry, Tarek A ^d   Filippi, Massimo ^a  

^a Dept Neurosci Sci Inst Osp S ^*  (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Gadolinium enhanced; Multiple sclerosis; Standard dose; Triple dose

Indexed keywords

GADOLINIUM;

ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DISEASE ACTIVITY; HUMAN; IMAGE ANALYSIS; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

BRAIN; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 0032863674     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0730-725X(99)00046-6     Document Type: Article

References (20)

1. Barkhof F., Scheltens P., Frequin S.T.M.F., et al. Relapsing-remitting multiple sclerosis Sequential enhanced MR imaging versus clinical findings in determining disease activity . Am. J. Roentgenol. 159:1992;1041-1047.
2. Harris J.O., Frank J.A., Patronas N., McFarlin D.E., McFarland H.F. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis Implications for clinical trials and natural history . Ann. Neurol. 29:1991;548-555.
3. Miller D.H., Barkhof F., Nauta J.J.P. Gadolinium enhancement increased the sensitivity of MRI in detecting disease activity in MS. Brain. 116:1993;1077-1094.
4. Filippi M., Miller D.H. MRI in the differential diagnosis and monitoring the treatment of multiple sclerosis. Curr. Opin. Neurol. 9:1996;176-186.
5. Miller D.H., Albert P.S., Barkhof F., et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann. Neurol. 39:1996;6-16.
6. Koudriavtseva T., Thompson A.J., Fiorelli M., et al. Gadolinium-enhanced MRI predicts clinical and MRI activity in relapsing-remitting multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 62:1997;285-287.
7. 2 lesion volume in multiple sclerosis. Ann. Neurol. 43:1998;332-339.
8. Filippi M., Horsfield M.A., Tofts P.S., Barkhof F., Thompson A.J., Miller D.H. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain. 118:1995;1601-1612.
9. Barkhof F., Filippi M., van Waesberghe J.H., et al. Improving inter-observer variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. Neurology. 49:1997;1682-1688.
10. Filippi M., Yousry T., Campi A., et al. Comparison of triple dose versus standard dose gadolinium-DTPA for detection of MRI enhancing lesions in patients with MS. Neurology. 46:1996;379-384.
11. Lai M., Hodgson T., Gawne-Cain M., et al. A preliminary study into the sensitivity of disease activity detection by serial weekly magnetic resonance imaging in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 60:1996;339-341.
12. Silver N.C., Good C.D., Barker G.J., et al. Sensitivity of contrast enhanced MRI in multiple sclerosis Effects of gadolinium dose, magnetization transfer contrast and delayed imaging . Brain. 120:1997;1149-1161.
13. Filippi M., Rovaris M., Capra R., et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis Implications for clinical trials . Brain. 121:1998;2011-2020.
14. Filippi M., Rovaris M., Capra R., et al. Serial standard- and triple dose to monitor the effect of interferon β-1a on multiple sclerosis activity. Neurology. 50:(Suppl 4):1998;A323. [abstract].
15. Poser C.M., Paty D.W., Scheinberg L., et al. New diagnostic criteria for multiple sclerosis Guidelines for research protocols . Ann. Neurol. 13:1983;227-231.
16. 2-weighted images . J. Neurol. 244:1997;266-270.
17. Lublin F.D., Reingold S.C. The National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology. 46:1996;907-911.
18. Filippi M., Barkhof F., Bressi S., Yousry T.A., Miller D.H. Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis. Multiple Sclerosis. 3:1997;226-230.
19. Filippi M., Rocca M.A., Rizzo G., et al. Magnetization transfer ratios in multiple sclerosis lesions enhancing after different dose of gadolinium. Neurology. 50:1998;1289-1293.
20. Rovaris M., Mastronardo G., Gasperini C., et al. MRI evolution of new MS lesions enhancing after different doses of gadolinium. Acta. Neurol. Scand. 98:1998;90-93.